Microglia, the immune cells that patrol and maintain the brain, depend on a specific fuel strategy to do their job well. This review from Cedars-Sinai argues that as the brain ages, microglia switch from efficient mitochondrial energy production to a faster but sloppier reliance on glucose fermentation, accumulate fat droplets they cannot burn, and drift into a chronically inflamed, poorly functioning state. The authors position this metabolic switch not as a side effect of brain aging but as one of its drivers, and note that the switch happens earlier and more strongly in female mice. They argue that targeting microglial metabolism, through mTOR, AMPK, or PPAR-gamma signaling, is a plausible therapeutic route for Alzheimer’s and Parkinson’s disease.
The brain has its own cleaning crew. Microglia, immune cells that make up roughly a tenth of brain cells, spend their lives crawling through neural tissue, pruning unused synapses, swallowing dying cells, and clearing protein debris. When they work, the brain stays tidy. When they stop working, debris accumulates and inflammation becomes chronic.
A review published in Aging Cell by Seokjo Kang and Helen Goodridge at Cedars-Sinai Medical Center makes the case that what determines whether microglia work or fail is not primarily what genes they carry, but what fuel they burn.
The big idea is straightforward. A healthy, resting microglial cell runs mostly on oxidative phosphorylation, the slow and highly efficient mitochondrial process that extracts maximum energy from glucose and fat. This suits a cell whose day job is patient surveillance. When a microglial cell detects a threat, it flips to glycolysis, fermenting glucose rapidly for a burst of energy and the building blocks needed to make inflammatory signals. This is the same switch that immune cells throughout the body use, and in the short term it is appropriate.
The problem, the authors argue, is that in the aging brain the switch gets stuck. Mitochondria in old microglia become less efficient, and the cells settle permanently into the glycolytic, inflammatory setting. Some accumulate lipid droplets they can no longer burn, becoming what researchers call lipid-droplet-accumulating microglia, a state marked by poor debris clearance and elevated oxidative stress. Others adopt a disease-associated profile that initially helps contain amyloid plaques but becomes progressively less effective as disease advances.
This creates a plausible causal loop. Metabolically stuck microglia clear less debris, debris drives more inflammation, and inflammation reinforces the metabolic state. Genetic risk factors for Alzheimer’s fit this picture: TREM2 and APOE, the two strongest genetic determinants of late-onset Alzheimer’s, both regulate lipid handling and both shape microglial fuel use.
The review’s most concrete claim concerns sex. Aged female microglia in mice shift toward glycolysis more strongly than male microglia, show more disease-associated cells, and generate more inflammation, a pattern the authors link to AKT-mTOR-HIF1-alpha signaling and complement C3a signaling. Estrogen appears to restrain the same programs, which offers a mechanistic hypothesis for why roughly two-thirds of Alzheimer’s patients are women.
The authors are candid about the limits. Almost all of this comes from mice, and most metabolic measurements come from microglia removed from the brain and studied in a dish, where they behave differently.
Insights
To show what the underlying evidence actually looks like, consider the sex-difference finding, the review’s most quantitative theme. The primary studies it cites report only p-values, with five to six mice per group. Working backward from those numbers, a result reported at p less than 0.05 with six animals per group corresponds to a standardized effect size (Cohen’s d) of about 1.3, and p less than 0.01 to about 1.8. Those look enormous, but that is precisely the problem: with samples that small, only huge apparent effects can reach significance, and the true effects are almost certainly much smaller. This is a well-documented statistical inflation, not a sign of a powerful intervention.
The one defensible real-world takeaway is epidemiological, not experimental: about two-thirds of Americans living with Alzheimer’s are women, and this review offers a candidate biological reason rather than a purely demographic one.
Context and Source
- Open Access Paper: Metabolic Reprogramming of Brain Microglia: Implications for Aging and Aging-Associated Neurodegenerative Diseases
- Institution: Board of Governors Regenerative Medicine Institute and Research Division of Immunology, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Country: United States
- Journal: Aging Cell (Wiley, on behalf of the Anatomical Society)
- Article type: Mini Review
- Funding: Alzheimer’s Association grant ABA-25-1372697 to H.S.G., a Center for Research in Women’s Health Science fellowship to S.K., and Cedars-Sinai institutional funds.
- Impact evaluation: The impact score of this journal is 7.7 (2025 Journal Citation Reports Impact Factor; Scopus CiteScore 13.8), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.